Vincent Calvez

Q: What Schools Are Affiliated With Vincent Calvez

Vincent Calvez is affiliated with the following schools: École normale supérieure de Lyon, Sorbonne University

Vincent Calvez's AcademicInfluence.com Rankings

Vincent Calvez

Mathematics

#4572

World Rank

#6471

Historical Rank

Measure Theory

#1597

World Rank

#1975

Historical Rank

mathematics Degrees

Download Badge

Mathematics

Why Is Vincent Calvez Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Vincent Calvez is a French mathematician. He is currently a directeur de recherche at the Institute Camille Jordan at the Claude Bernard University Lyon 1. He is known for his work in mathematical modeling in biology, especially in the movement of bacteria.

(See a Problem?)

Vincent Calvez's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease (1998) (584)
Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team). (2000) (407)
Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma (1995) (394)
2011 update of the drug resistance mutations in HIV-1. (2011) (339)
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study (2001) (306)
Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro (2008) (300)
Update of the drug resistance mutations in HIV-1: March 2013. (2013) (237)
Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected Patients (2004) (217)
Convergence of the Mass-Transport Steepest Descent Scheme for the Subcritical Patlak-Keller-Segel Model (2008) (215)
Volume effects in the Keller-Segel model : energy estimates preventing blow-up (2006) (210)
Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. (1999) (203)
HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. (1999) (185)
2017 Update of the Drug Resistance Mutations in HIV-1. (2016) (177)
Directional persistence of chemotactic bacteria in a traveling concentration wave (2011) (177)
The parabolic-parabolic Keller-Segel model in R2 (2008) (168)
Rituximab therapy for HIV-associated Castleman disease. (2003) (149)
2014 Update of the drug resistance mutations in HIV-1. (2014) (146)
Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel (2018) (146)
The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients (2021) (144)
Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers (2021) (144)
The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation (2008) (143)
2019 update of the drug resistance mutations in HIV-1. (2019) (142)
Transient Mobilization of Human Immunodeficiency Virus (HIV)-Specific CD4 T-Helper Cells Fails To Control Virus Rebounds during Intermittent Antiretroviral Therapy in Chronic HIV Type 1 Infection (2001) (141)
2015 Update of the Drug Resistance Mutations in HIV-1. (2015) (140)
Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. (1997) (136)
Resistance profile and cross‐resistance of HIV‐1 among patients failing a non‐nucleoside reverse transcriptase inhibitor‐containing regimen * (2001) (135)
Diagnosing Treponema pallidum in secondary syphilis by PCR and immunohistochemistry. (2007) (132)
Restoration of the immune system with anti-retroviral therapy. (1999) (130)
Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure (2004) (127)
A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy (2012) (126)
Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. (1999) (126)
PROSPECTIVE STUDY OF THE EFFECTS OF ANTIRETROVIRAL THERAPY ON KAPOSI SARCOMA– ASSOCIATED HERPESVIRUS INFECTION IN PATIENTS WITH AND WITHOUT KAPOSI SARCOMA (2002) (126)
Nicotinamide inhibits Propionibacterium acnes-induced IL-8 production in keratinocytes through the NF-kappaB and MAPK pathways. (2009) (123)
Invasion fronts with variable motility: Phenotype selection, spatial sorting and wave acceleration (2012) (112)
Identification of Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Specific Cytotoxic T-Lymphocyte Epitopes and Evaluation of Reconstitution of KSHV-Specific Responses in Human Immunodeficiency Virus Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy (2002) (107)
Genotypic Inhibitory Quotient as Predictor of Virological Response to Ritonavir-Amprenavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients (2003) (106)
Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. (2000) (104)
Mathematical Description of Bacterial Traveling Pulses (2009) (98)
HHV-8 and multiple myeloma in France (1997) (98)
Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. (2009) (98)
High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. (2004) (96)
Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection (2002) (93)
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. (2006) (92)
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452) (2008) (92)
Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097) (2004) (91)
Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002–2011 survey (2012) (87)
Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy. (2011) (85)
INTERLEUKIN-2 ACCELERATES CD4 CELL RECONSTITUTION IN HIV-INFECTED PATIENTS WITH SEVERE IMMUNOSUPPRESSION DESPITE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: THE ILSTIM STUDY—ANRS 082 (2002) (84)
CD8hi+CD57+ T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity. (1998) (84)
Evolution of viral quasispecies during SARS-CoV-2 infection (2020) (84)
Dynamics of HIV-Specific CD8+ T Lymphocytes with Changes in Viral Load1 (2000) (83)
Clinical and spectroscopic improvement in HIV-associated cognitive impairment (2001) (82)
Circulating Interleukin-6 Levels Correlate with Residual HIV Viraemia and Markers of Immune Dysfunction in Treatment-Controlled HIV-Infected Patients (2012) (82)
Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In Vitro and In Vivo (2009) (80)
Clinically Relevant Genotype Interpretation of Resistance to Didanosine (2005) (79)
Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus Type 1 Variants with Insertions or Deletions in the Reverse Transcriptase (RT): Multicenter Study of Patients Treated with RT Inhibitors (2001) (76)
Persistence of Multidrug-Resistant HIV-1 without Antiretroviral Treatment 2 Years after Sexual Transmission (2003) (75)
The one-dimensional Keller–Segel model with fractional diffusion of cells (2009) (74)
Clinically relevant interpretation of genotype for resistance to abacavir (2003) (73)
Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. (2010) (73)
Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir (2016) (70)
Clinically Validated Genotype Analysis: Guiding Principles and Statistical Concerns (2004) (70)
GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy * (2004) (69)
Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. (2005) (68)
Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. (2011) (68)
Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients (2006) (68)
The influence of highly active antiretroviral therapy on AIDS‐associated Kaposi's sarcoma (1999) (68)
Immunogenicity of Mutations Induced by Nucleoside Reverse Transcriptase Inhibitors for Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Cells (2000) (68)
Front acceleration by dynamic selection in Fisher population waves. (2012) (67)
Mathematical modelling of the atherosclerotic plaque formation (2009) (67)
Human Immunodeficiency Virus (HIV) Type 1 Reverse Transcriptase Resistance Mutations in Hepatitis B Virus (HBV)-HIV-Coinfected Patients Treated for HBV Chronic Infection Once Daily with 10 Milligrams of Adefovir Dipivoxil Combined with Lamivudine (2002) (67)
Anti-endothelial cell auto-antibodies in hepatitis C virus mixed cryoglobulinemia. (1999) (66)
Fatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver‐transplant recipients (2004) (66)
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. (2008) (66)
Clinical features and contribution of virological findings to the management of Kaposi sarcoma in organ-allograft recipients. (2000) (66)
Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors (2017) (65)
Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. (2007) (63)
Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients (2003) (63)
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. (2010) (63)
Blow-up, Concentration Phenomenon and Global Existence for the Keller–Segel Model in High Dimension (2010) (63)
Travelling waves for the cane toads equation with bounded traits (2013) (63)
Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression. (2016) (63)
Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load.The RESTIM and COMET Study Groups. (2000) (62)
Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals (2010) (62)
Predictive value of HIV-1 genotypic resistance test interpretation algorithms. (2009) (62)
Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients (2005) (61)
Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease. (2007) (61)
Size distribution dependence of prion aggregates infectivity. (2009) (61)
Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali. (2010) (60)
Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19 (2020) (57)
CD4+Ki67+ lymphocytes in HIV‐infected patients are effector T cells accumulated in the G1 phase of the cell cycle (2000) (56)
Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. (2001) (55)
Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication (2005) (55)
Repeated HIV‐1 resistance genotyping external quality assessments improve virology laboratory performance (2006) (55)
HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy (2002) (55)
Prion dynamics with size dependency–strain phenomena (2010) (54)
National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. (2013) (54)
Clinically Relevant Interpretation of Genotype and Relationship to Plasma Drug Concentrations for Resistance to Saquinavir-Ritonavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients (2004) (53)
TLR-2 Recognizes Propionibacterium acnes CAMP Factor 1 from Highly Inflammatory Strains (2016) (53)
Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia. (2016) (53)
Efficacy and Tolerability of Stavudine plus Lamivudine in Treatment-Naive and Treatment-Experienced Patients with HIV-1 Infection (1998) (53)
Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. (2009) (53)
Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial (2016) (53)
Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml (2011) (52)
Substitutions in the capsids of poliovirus mutants selected in human neuroblastoma cells confer on the Mahoney type 1 strain a phenotype neurovirulent in mice (1994) (52)
Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes (2009) (52)
Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients (2008) (52)
Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy. (2005) (51)
Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). (2005) (51)
Mathematical and numerical modeling of early atherosclerotic lesions (2010) (51)
Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy. (2014) (51)
In silico investigation of the new UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 variants with a focus at the ACE2-Spike RBD interface (2021) (51)
Concordance between Two Phenotypic Assays and Ultradeep Pyrosequencing for Determining HIV-1 Tropism (2011) (50)
Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. (2015) (50)
The level of human immunodeficiency virus (HIV) type 1 RNA in cerebrospinal fluid as a marker of HIV encephalitis. (1998) (50)
Impact of Stavudine Phenotype and Thymidine Analogues Mutations on Viral Response to Stavudine plus Lamivudine in Altis 2 Anrs Trial (2001) (50)
The Origins of Concentric Demyelination: Self-Organization in the Human Brain (2007) (50)
Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy (2010) (49)
Refined asymptotics for the subcritical Keller-Segel system and related functional inequalities (2010) (49)
HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment. (2000) (49)
Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital (2020) (48)
Global Existence for a Kinetic Model of Chemotaxis via Dispersion and Strichartz Estimates (2007) (48)
New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. (2014) (48)
In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2–Spike RBD Interface (2021) (47)
Equilibria of homogeneous functionals in the fair-competition regime (2016) (47)
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses. (2013) (47)
Quantitative analysis of human mitochondrial DNA using a real‐time PCR assay (2003) (46)
Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study (2001) (46)
No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients (2005) (46)
Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors (2006) (46)
Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. (2008) (46)
Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-Naïve Patients Infected with Non-B HIV-1 Subtypes (2009) (46)
HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs. (2012) (46)
Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20 (2004) (45)
Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial (2018) (44)
Predictive Genotypic Algorithm for Virologic Response to Lopinavir-Ritonavir in Protease Inhibitor-Experienced Patients (2007) (44)
When and how to use maraviroc in HIV-infected patients (2009) (44)
Stavudine Resistance: An Update on Susceptibility following Prolonged Therapy (1999) (43)
Quantification of Kaposi's sarcoma-associated herpesvirus in blood, oral mucosa, and saliva in patients with Kaposi's sarcoma. (2004) (42)
E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure (2012) (42)
Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists. (2010) (42)
Optimal use of maraviroc in clinical practice. (2008) (42)
HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen (2005) (41)
Quantifying HIV transmission flow between high-prevalence hotspots and surrounding communities: a population-based study in Rakai, Uganda (2020) (41)
Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission. (2015) (41)
Factors Associated with Virological Response to Etravirine in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-1-Infected Patients (2009) (40)
Low-Rate Emergence of Thymidine Analogue Mutations and Multi-Drug Resistance Mutations in the HIV-1 Reverse Transcriptase Gene in Therapy-Naive Patients Receiving Stavudine plus Lamivudine Combination Therapy (2000) (40)
Kaposi's Sarcoma Associated with Previous Human Herpesvirus 8 Infection in Heart Transplant Recipients (2002) (39)
Precise missense and silent point mutations are fixed in the genomes of poliovirus mutants from persistently infected cells (1993) (39)
Modified Keller-Segel system and critical mass for the log interaction kernel (2006) (38)
Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. (2005) (38)
Co-infection of SARS-CoV-2 with other respiratory viruses and performance of lower respiratory tract samples for the diagnosis of COVID-19 (2020) (38)
Evaluation of the use of dried spots and of different storage conditions of plasma for HIV‐1 RNA quantification (2007) (37)
Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategy. (2000) (37)
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. (2011) (37)
Self-similarity in a general aggregation–fragmentation problem. Application to fitness analysis (2010) (37)
Kaposi's sarcoma herpesvirus and HIV‐1 seroprevalences in prostitutes in Djibouti (2002) (37)
A mathematical model for mechanotransduction at the early steps of suture formation (2013) (36)
First cases of Omicron in France are exhibiting mild symptoms, November 2021–January 2022 (2022) (35)
Polymorphism of the Human Immunodeficiency Virus Type 1 (HIV-1) Protease Gene and Response of HIV-1-Infected Patients to a Protease Inhibitor (1999) (35)
Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen (2018) (35)
Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir (2007) (35)
Seroprevalence of human herpesvirus-8 in healthy subjects and patients with AIDS-associated and classical Kaposi's sarcoma in France. (1998) (35)
Human herpesvirus 8 and renal transplantation. (1999) (35)
Impact of Discrepancies between the Abbott RealTime and Cobas TaqMan Assays for Quantification of Human Immunodeficiency Virus Type 1 Group M Non-B Subtypes (2009) (34)
KSHV after an organ transplant: should we screen? (2007) (34)
Effect of antiretroviral drugs on the quality of semen (2011) (33)
Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug. (2009) (33)
Confinement by biased velocity jumps: aggregation of Escherichia coli (2014) (33)
Early Virological Failure in Naive Human Immunodeficiency Virus Patients Receiving Saquinavir (Soft Gel Capsule)-Stavudine-Zalcitabine (MIKADO Trial) Is Not Associated with Mutations Conferring Viral Resistance (2000) (33)
HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART (2007) (33)
HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis (2010) (33)
Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting. (2012) (33)
Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms (2010) (32)
Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients (2008) (32)
Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia (2016) (32)
High Prevalence of Antiretroviral Drug Resistance among HIV-1-Untreated Patients in Guinea-Conakry and in Niger (2011) (32)
Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial. (2015) (31)
Prevalence of human herpesvirus 8 infection measured by antibodies to a latent nuclear antigen in patients with various dermatologic diseases. (1998) (31)
The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients (2021) (31)
Plasma Hypercoagulability Is Correlated to Plasma HIV Load* (1998) (31)
Viral loads in clinical samples of men with monkeypox virus infection: a French case series (2022) (31)
Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019 (2020) (31)
Similar Evolution of Cellular HIV-1 DNA Level in Darunavir/Ritonavir Monotherapy versus Triple Therapy in MONOI –ANRS136 Trial over 96 Weeks (2012) (30)
Bilateral symmetrical enhancing brainstem lesions: an unusual presentation of primary CNS lymphoma (1999) (30)
A kinetic eikonal equation (2012) (30)
The future of integrase inhibitors of HIV-1. (2012) (29)
HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen (2007) (29)
Human herpesvirus 8 infection, Castleman's disease and POEMS syndrome (1999) (29)
Foscarnet Salvage Therapy for Patients with Late-Stage HIV Disease and Multiple Drug Resistance (2005) (29)
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. (2012) (29)
Global existence for the kinetic chemotaxis model without pointwise memory effects, and including internal variables (2008) (28)
Genetic Diversity and Drug Resistance Mutations in HIV type 1 from Untreated Patients in Bamako, Mali (2007) (28)
Presence of HIV-1 R5 Viruses in Cerebrospinal Fluid Even in Patients Harboring R5X4/X4 Viruses in Plasma (2009) (28)
Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection. (2007) (28)
Bridging β-Cyclodextrin Prevents Self-Inclusion, Promotes Supramolecular Polymerization, and Promotes Cooperative Interaction with Nucleic Acids. (2018) (28)
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients (2004) (28)
Critical mass phenomenon for a chemotaxis kinetic model with spherically symmetric initial data (2009) (28)
[Antiretroviral therapy and immune reconstitution]. (1999) (28)
Relationship between mutations in HIV‐1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre‐treated HIV infected patients (2007) (28)
Virological and pharmacological factors associated with virological response to salvage therapy after an 8‐week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097) (2005) (27)
Line Probe Assay for Detection of Human Immunodeficiency Virus Type 1 Mutations Conferring Resistance to Nucleoside Inhibitors of Reverse Transcriptase: Comparison with Sequence Analysis (1998) (27)
Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study (2017) (27)
Identification of a region of the poliovirus genome involved in persistent infection of HEp-2 cells (1993) (27)
Modeling Edar expression reveals the hidden dynamics of tooth signaling center patterning (2019) (27)
Cluster formation for multi-strain infections with cross-immunity. (2005) (27)
Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments (2014) (27)
Comparison of Tests and Procedures to Build Clinically Relevant Genotypic Scores: Application to the Jaguar Study (2005) (26)
No effect of protease inhibitor on clinical and virological evolution of Castleman's disease in an HIV-1-infected patient. (1997) (26)
The geometry of diffusing and self-attracting particles in a one-dimensional fair-competition regime (2016) (26)
Resistance to novel drug classes (2009) (26)
G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance. (2015) (26)
Propagation in a Kinetic Reaction-Transport Equation: Travelling Waves And Accelerating Fronts (2013) (25)
Human herpesvirus-8 seroconversions after renal transplantation. (2001) (25)
Lack of evidence of human herpesvirus 8 DNA sequences in HIV‐negative patients with various lymphoproliferative disorders of the skin (1997) (25)
Structural effects of amino acid variations between B and CRF02‐AG HIV‐1 integrases (2008) (25)
Prevalence and Conditions of Selection of E44D/A and V118I Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in Clinical Practice (2001) (25)
Catch Me If You Can: A Spatial Model for a Brake-Driven Gene Drive Reversal (2018) (24)
Final analysis of the Trilège induction-maintenance trial: results at 18 months (2002) (24)
Efficacy and Safety of Ritonavir/Indinavir 100/400 Mg Twice Daily in Combination with Two Nucleoside Analogues in Antiretroviral Treatment-Naive HIV-Infected Individuals (2002) (24)
Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load. (2017) (24)
Salvage Therapy with Atazanavir/Ritonavir Combined to Tenofovir in HIV-Infected Patients with Multiple Treatment Failures: Randomized Anrs 107 Trial (2006) (24)
Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or Monotherapy (2010) (24)
Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor‐sparing therapy in patients with lipoatrophy: results from the 96‐week randomized ANRS 108 NoNuke Trial (2008) (24)
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes. (2014) (24)
A Predictive Model for Yeast Cell Polarization in Pheromone Gradients (2016) (24)
Traveling Wave and Aggregation in a Flux-Limited Keller-Segel Model (2017) (24)
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. (2016) (23)
Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease. (2008) (23)
High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali. (2014) (23)
Hyperbolic traveling waves driven by growth (2011) (23)
HIV‐1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations (2009) (22)
Comparison of two genotypic algorithms to determine HIV‐1 tropism * (2008) (22)
Analysis of a Nonlocal Model for Spontaneous Cell Polarization (2012) (22)
Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients (2007) (22)
MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study (2004) (22)
Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing. (2015) (22)
Medical features of COVID-19 and influenza infection: A comparative study in Paris, France (2020) (21)
Seroprevalence and risk factors for HIV, HCV, HBV and syphilis among blood donors in Mali (2019) (21)
Chemotactic waves of bacteria at the mesoscale (2016) (21)
Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution (2005) (21)
Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients. (2020) (21)
A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure. (2013) (21)
Resistance mutations before and after tenofovir regimen failure in HIV‐1 infected patients (2005) (21)
Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients (2018) (21)
Prevalences of herpesviruses DNA sequences in salivary gland biopsies from primary and secondary Sjögren's syndrome using degenerated consensus PCR primers. (2003) (21)
Cell clones cured of persistent poliovirus infection display selective permissivity to the wild-type poliovirus strain Mahoney and partial resistance to the attenuated Sabin 1 strain and Mahoney mutants. (1995) (21)
Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients (2009) (20)
Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virological suppression (2016) (20)
Clinical Validation of Saquinavir/Ritonavir Genotypic Resistance Score in Protease-Inhibitor-Experienced Patients (2007) (19)
The EPIICAL project: an emerging global collaboration to investigate immunotherapeutic strategies in HIV-infected children (2015) (19)
Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy. (2014) (19)
Interruption of Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapy for 2 Months Has No Effect on Levels of Human Immunodeficiency Virus Type 1 in Plasma of Patients Harboring Viruses with Mutations Associated with Resistance to NNRTIs (2003) (19)
Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy. (2012) (19)
Fatal Encephalitis Caused by Cristoli Virus, an Emerging Orthobunyavirus, France (2020) (19)
Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010. (2013) (19)
A single amino-acid change in a highly conserved motif of gp41 elicits HIV-1 neutralization and protects against CD4 depletion. (2013) (18)
Comparison of the Dynamics of Resistance-Associated Mutations to Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors after Cessation of Antiretroviral Combination Therapy (2004) (18)
Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study (2008) (18)
Characterization update of HIV-1 M subtypes diversity and proposal for subtypes A and D sub-subtypes reclassification (2018) (18)
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial. (2008) (18)
Plasma and cerebrospinal fluid human immunodeficiency virus type-1 (HIV-1) RNA levels in HIV-related cognitive impairment. (1999) (18)
Asymptotic analysis of a quantitative genetics model with nonlinear integral operator (2018) (18)
Transmitted antiretroviral drug resistance in newly HIV-infected and untreated patients in Ségou and Bamako, Mali. (2013) (18)
A one-dimensional Keller-Segel equation with a drift issued from the boundary (2009) (18)
Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19 (2020) (17)
Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing (2018) (17)
Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART (2018) (17)
Susceptibility of peripheral blood mononuclear cells to apoptosis is correlated to plasma HIV load. (1998) (17)
High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400/100 mg twice a day) plus two nucleoside reverse transcriptase inhibitors. (2003) (17)
Markov modelling of changes in HIV‐specific cytotoxic T‐lymphocyte responses with time in untreated HIV‐1 infected patients (2003) (17)
Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients (2010) (16)
Particle approximation of the one dimensional Keller-Segel equation, stability and rigidity of the blow-up (2014) (16)
Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients. (2011) (16)
Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice. (2015) (16)
The tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4+ T cells from HIV-1 infected patients (2014) (16)
Interpretation of SARS-CoV-2 replication according to RT-PCR crossing threshold value (2021) (16)
Systematic Review to Determine the Prevalence of Transmitted Drug Resistance Mutations to Rilpivirine in HIV-Infected Treatment-Naive Persons (2016) (16)
Stability of HIV RNA in plasma specimens stored at different temperatures (2008) (16)
Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism. (2011) (16)
P‐glycoprotein in blood CD4 cells of HIV‐1‐infected patients treated with protease inhibitors (2003) (15)
Antiretroviral Therapy with a Twice-Daily Regimen Containing 400 Milligrams of Indinavir and 100 Milligrams of Ritonavir in Human Immunodeficiency Virus Type 1-Infected Women during Pregnancy (2008) (15)
Non-local competition slows down front acceleration during dispersal evolution (2018) (15)
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV‐1 Non‐nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine (2011) (15)
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. (2020) (15)
Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination. (2016) (15)
Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries (2018) (15)
HIV-1 Dynamics and Coreceptor Usage in Maraviroc-Treated Patients with Ongoing Replication (2012) (15)
Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years (2011) (14)
The parabolic-parabolic Keller-Segel model in $\mathbb{R}^2$ (2007) (14)
Mathematical description of concentric demyelination in the human brain: Self-organization models, from Liesegang rings to chemotaxis (2008) (14)
Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B. (2013) (14)
Positive Impact of HIV-1 gag Cleavage Site Mutations on the Virological Response to Darunavir Boosted with Ritonavir (2011) (14)
The use of human immunodeficiency virus resistance tests in clinical practice. (2010) (14)
Genotypic Resistance Analysis of the Virological Response to Fosamprenavir-Ritonavir in Protease Inhibitor-Experienced Patients in CONTEXT and TRIAD Clinical Trials (2008) (13)
Direct gene transfer of a plasmid carrying the herpes simplex virus-thymidine kinase gene (HSV-TK) in transplanted murine melanoma: in vivo study. (1996) (13)
Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies (2022) (13)
Neurological diseases of unknown etiology: Brain-biopsy diagnostic yields and safety. (2020) (13)
Upgraded Cobas Ampliprep-Cobas TaqMan Version 2.0 HIV-1 RNA Quantification Assay versus First Version: Correction of Underestimations (2011) (13)
Characterization of a Propionibacterium acnes Surface Protein as a Fibrinogen-Binding Protein (2017) (13)
Prevalence of cervical HPV infection, sexually transmitted infections and associated antimicrobial resistance in women attending cervical cancer screening in Mali. (2021) (13)
Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance. (2015) (12)
Lack of evidence of an association between HHV-8 and multiple myeloma (1998) (12)
Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance (2018) (12)
Emerging Mutations and Associated Factors in Patients Displaying Treatment Failure on An Etravirine-Containing Regimen (2012) (12)
Pre-COVID-19 humoral immunity to common coronaviruses does not confer cross-protection against SARS-CoV-2 (2020) (12)
Parenteral transmission of Kaposi's sarcoma-associated herpesvirus. (1998) (12)
Impact of HIV-1 Reverse Transcriptase Polymorphism at Codons 211 and 228 on Virological Response to Didanosine (2005) (12)
Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus–infected patients: Results from a randomized control trial (2002) (12)
International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase (2010) (12)
Uniqueness of stationary states for singular Keller–Segel type models (2019) (12)
No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir (2018) (12)
Author Correction: Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers (2021) (12)
Virus-free transfer of the herpes simplex virus thymidine kinase gene followed by ganciclovir treatment induces tumor cell death. (1996) (11)
Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients (2002) (11)
Risk factors for raltegravir resistance development in clinical practice. (2012) (11)
Uniqueness of the viscosity solution of a constrained Hamilton–Jacobi equation (2018) (11)
Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen (2018) (11)
Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen (2018) (11)
Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART (2018) (11)
Performance of serum apolipoprotein-A1 as a sentinel of Covid-19 (2020) (11)
Usefulness of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for Diagnosis and Monitoring of KSHV-Associated Diseases (2018) (11)
Clinical presentation of Covid-19 in health care workers from a French University Hospital (2020) (11)
Efficacy of etravirine combined with darunavir or other ritonavir‐boosted protease inhibitors in HIV‐1‐infected patients: an observational study using pooled European cohort data (2015) (11)
New Kaposi's sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologies. (2020) (11)
Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV‐1‐infected patients: A French nationwide study (2005) (11)
Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy. (2007) (11)
Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France (2019) (11)
The G 140 S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q 148 H mutation (2009) (10)
A Polymorphism at Position 400 in the Connection Subdomain of HIV-1 Reverse Transcriptase Affects Sensitivity to NNRTIs and RNaseH Activity (2013) (10)
Coreceptor usage in different reservoirs (2012) (10)
Existence of recombination-selection equilibria for sexual populations (2017) (10)
Risk Factors for Selection of the L74I Reverse Transcriptase Mutation in Human Immunodeficiency Virus Type 1-Infected Patients (2006) (10)
Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations. (2020) (10)
AIDS-Related Primary Lymphoma of the Pleural Cavity (1998) (10)
M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients. (2020) (10)
National survey of the prevalence and conditions of selection of HIV‐1 reverse transcriptase K70E mutation (2008) (10)
MIKADO: a multicentre, open‐label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine (2001) (10)
External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inhibitor-experienced patients. (2006) (9)
Variability of the HIV-1 3' polypurine tract (3'PPT) region and implication in integrase inhibitor resistance. (2019) (9)
Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm3 at the time of diagnosis according to HIV‐1 coreceptor tropism (2012) (9)
Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients. (2021) (9)
Non-linear eigenvalue problems arising from growth maximization of positive linear dynamical systems (2014) (9)
Salivary lactoferrin is recognized by the human herpesvirus-8. (2005) (9)
Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors. (2013) (9)
Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers (2021) (9)
Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants (2018) (9)
A Lyapunov function for a two-chemical species version of the chemotaxis model (2006) (9)
Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage (2015) (9)
Reply to Das and Berkhout, “How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir” (2018) (9)
Blow-up dynamics of self-attracting diffusive particles driven by competing convexities (2013) (9)
Asymptotic Behavior of a Two-Dimensional Keller–Segel Model with and without Density Control (2008) (9)
Shared HCV Transmission Networks among HIV-1 Positive and Negative Men Having Sex with Men by Ultra-Deep Sequencing (2019) (9)
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in (2009) (9)
E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations. (2012) (9)
A Very Low Geno2pheno False Positive Rate Is Associated with Poor Viro-Immunological Response in Drug-Naïve Patients Starting a First-Line HAART (2014) (9)
Kinetic Models of Chemotaxis (2012) (9)
Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence? (2019) (9)
Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey (2007) (8)
Caution is needed in interpreting HIV transmission chains by ultradeep sequencing (2019) (8)
Lack of Evidence of Any Association Between Human Herpesvirus 8 and Various Skin Tumors From Both Immunocompetent and Immunosuppressed Patients (1997) (8)
Efficacy of Dideoxynucleosides against Human Foamy Virus and Relationship to Its Reverse Transcriptase Amino Acid Sequence and Structure (2001) (8)
Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing. (2019) (8)
A long-term follow-up of an HIV type 1-infected patient reveals a coincidence of Nef-directed cytotoxic T lymphocyte effectors and high incidence of epitope-deleted variants. (2001) (8)
Large deviations for velocity-jump processes and non-local Hamilton-Jacobi equations (2016) (8)
Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial). (2015) (8)
Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients (2019) (8)
HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. (2019) (8)
Performance of genotypic algorithms for predicting tropism of HIV-1CRF02_AG subtype. (2016) (8)
Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma (2017) (8)
Pharmacokinetics, Safety and Efficacy of Ritonavir-Boosted Atazanavir (300/100 mg Once Daily) in HIV-1-Infected Pregnant Women (2015) (8)
Disparities in HIV‐1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations (2017) (8)
Limiting Hamilton-Jacobi equation for the large scale asymptotics of a subdiffusion jump-renewal equation (2016) (8)
Mutations in the human immunodeficiency virus type 1 reverse transcriptase gene observed in stavudine and didanosine strains obtained by in vitro passages. (1998) (8)
In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors (2012) (7)
Kaposi’s Sarcoma-Associated Herpesvirus, the Etiological Agent of All Epidemiological Forms of Kaposi’s Sarcoma (2021) (7)
Persistent Poliovirus Infection: Development of New Models with Cell Lines a (1995) (7)
Pharmacokinetics, protein‐binding‐adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment‐naïve HIV‐infected patients * (2010) (7)
Front propagation in a kinetic reaction-transport equation (2013) (7)
Decreased Sensitivity of Rapid Antigen Test Is Associated with a Lower Viral Load of Omicron than Delta SARS-CoV-2 Variant (2022) (7)
Impact of Y 143 HIV-1 integrase mutations on resistance to Raltegravir in vitro and in vivo (2009) (7)
XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants (2021) (7)
Analysis of a non local model for spontaneous cell polarisation (2011) (7)
Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma. (2015) (7)
Switch From Etravirine Twice Daily to Once Daily in Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant HIV-Infected Patients With Suppressed Viremia: The Monetra Study (2012) (7)
Virological and immunological impact of non-nucleoside reverse transcriptase inhibitor withdrawal in HIV-infected patients with multiple treatment failures (2004) (7)
Performance of genotypic algorithms for predicting tropism for HIV-1 CRF01_AE recombinant. (2018) (7)
Increase of HIV-1 Pro-Viral Dna per Million Peripheral Blood Mononuclear Cells in Patients with Advanced HIV Disease (Cd4<200 Cells/Mm3) Receiving Interleukin 2 Combined with Haart Versus Haart Alone (Anrs-082 Trial) (2002) (7)
Pitfalls of HIV genotypic tropism testing after treatment interruption. (2013) (6)
Lack of evidence of any association between human herpesvirus 8 and various skin tumors from both immunocompetent and immunosuppressed patients. (1997) (6)
Detection of HHV-8 in Sjögren's syndrome. (1996) (6)
A structural model of the VEGF signalling pathway: emergence of robustness and redundancy properties. (2012) (6)
Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes. (2015) (6)
Less-drug regimen including atazanavir in maintenance treatment of HIV infection: how, who, when, why? (2017) (6)
Horizontal gene transfer: numerical comparison between stochastic and deterministic approaches (2019) (6)
Low Immune Response Rate of HIV-Infected Patients to a Single Injection of Hepatitis A Vaccine. (2020) (6)
Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B. (2013) (6)
New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations. (2019) (6)
First-line therapy with LPV/r vs NVP and 2 NRTIs in a developing country: W144 of a randomized trial (2014) (6)
The first locally acquired novel case of 2019-nCoV infection in a healthcare worker in the Paris area (2020) (6)
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study. (2022) (6)
Travelling Chemotactic Aggregates at Mesoscopic Scale and BiStability (2017) (6)
NUMERICAL STUDY OF THE STOPPING OF AURA DURING MIGRAINE (2010) (6)
A step ahead on the HIV collaboratory. (2009) (6)
No influence of human herpesvirus 8 infection on the progression of HIV‐1 infection in initially asymptomatic patients (2003) (5)
A REVIEW OF RECENT EXISTENCE AND BLOW-UP RESULTS FOR KINETIC MODELS OF CHEMOTAXIS (5)
Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection (2022) (5)
Connection Domain Mutations During Antiretroviral Treatment Failure in Mali: Frequencies and Impact on Reverse Transcriptase Inhibitor Activity (2012) (5)
New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017 (2019) (5)
Nosocomial transmission clusters and lineage diversity characterized by SARS-CoV-2 genomes from two large hospitals in Paris, France, in 2020 (2022) (5)
Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial Data (2012) (5)
Predictors of virologic response to ritonavir-boosted protease inhibitors. (2005) (5)
A Lyapunov function for a two-chemical version of the chemotaxis model (2003) (5)
Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients. (2016) (5)
Unexpected atazanavir-associated biliary lithiasis in an HIV-infected patient. (2012) (5)
Dynamics of lineages in adaptation to a gradual environmental change (2021) (5)
Identification of new genotypic cut‐off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial (2009) (5)
Second-line antiretroviral therapy failure and characterization of HIV-1 drug resistance patterns in children in Mali. (2019) (5)
[CCR5 antagonists: a new class of antiretrovirals]. (2009) (5)
Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice. (2012) (5)
Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies. (2013) (5)
Effects of cyclosporine and hydrocortisone on Kaposi's sarcoma-associated herpesvirus genome replication and cell apoptosis induction. (2001) (5)
Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study. (2015) (5)
Primary infection with human herpesvirus 8 in an HIV-1-infected patient. (2000) (5)
Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation (2022) (5)
Reduction of a stochastic model of gene expression: Lagrangian dynamics gives access to basins of attraction as cell types and metastabilty (2020) (5)
Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies (2018) (4)
Incomplete APOBEC 3 G / F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR 5 to CXCR 4 Usage (2015) (4)
INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels (2019) (4)
Ultradeep sequencing detection of the R263K integrase inhibitor drug resistance mutation (2017) (4)
Mutations in the 3'-PPT Lead to HIV-1 Replication without Integration (2022) (4)
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV‐1 reverse transcriptase (M184L and M184T) (2018) (4)
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS‐163 ETRAL Study (2019) (4)
Presence of Minority Resistant Variants After Failure of a Tenofovir, Emtricitabine, and Rilpivirine Regimen (2016) (4)
Poppers, by Inducing HHV-8 Virion Production, Can Act as a Promoter for HHV-8 Transmission in Men Who Have Sex With Men (2021) (4)
Scoring Methods for Building Genotypic Scores: An Application to Didanosine Resistance in a Large Derivation Set (2013) (4)
HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide. (2008) (4)
Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level. (2004) (4)
HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc (2015) (4)
Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response. (2015) (4)
Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score (2014) (4)
Concentric demyelination by self-organization: a new hypothesis for Baló's sclerosis (2007) (4)
Experience of indinavir/ritonavir 400/100 mg twice-daily highly active antiretroviral therapy-containing regimen in HIV-1-infected patients in Bamako, Mali: the NOGOMA Study. (2007) (4)
No HIV-1 molecular evolution on long term antiretroviral therapy initiated during primary HIV-1 infection. (2020) (4)
Optimal growth for linear processes with affine control (2012) (4)
Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V - The LAMRES Study. (2022) (4)
Discovery, SAR study and ADME properties of methyl 4-amino-3-cyano-1-(2-benzyloxyphenyl)-1H-pyrazole-5-carboxylate as an HIV-1 replication inhibitor. (2020) (4)
Numerical Simulation of the Dynamics of Molecular Markers Involved in Cell Polarization (2013) (4)
The First Locally Acquired Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Healthcare Worker in the Paris Area (2020) (3)
Characterization of a Cutibacterium acnes Camp Factor 1-Related Peptide as a New TLR-2 Modulator in In Vitro and Ex Vivo Models of Inflammation (2022) (3)
Pulled, pushed or failed: the demographic impact of a gene drive can change the nature of its spatial spread (2022) (3)
HHV-8 and multiple myeloma in (1997) (3)
Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey. (2021) (3)
Anti-gp41 antibody levels reflect HIV viral suppression and cellular reservoir in long-term antiretroviral-treated trial participants (2019) (3)
Decreased peripheral circulation of HIV-infected cells in a subset of long-term nonprogressors. The French ALT Study Group. (1999) (3)
2022 update of the drug resistance mutations in HIV-1. (2022) (3)
Seroprevalence and molecular diversity of Human Herpesvirus 8 among people living with HIV in Brazzaville, Congo (2021) (3)
Description of the L76V Resistance Protease Mutation in HIV-1 B and “Non-B” Subtypes (2013) (3)
Low hepatitis D seroprevalence in blood donors of Bamako, Mali (2019) (3)
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: evidences from literature. (2014) (3)
The best of both worlds: Combining population genetic and quantitative genetic models. (2021) (3)
Evaluation of Two HIV Rapid Diagnostic Tests in a Context of Strains' Genetic Diversity in Mali. (2018) (3)
High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2 (2022) (3)
Ultradeep sequencing reveals HIV-1 diversity and resistance compartmentalization during HIV-encephalopathy. (2020) (3)
[HIV drug resistance]. (2006) (3)
[HHV-8/KSHV. I - epidemiological and molecular aspects]. (2000) (3)
Efficacy and safety of tenofovir double‐dose in treatment‐experienced HIV‐infected patients: The tenoplus study (2007) (3)
A quantitative genetics model with sexual mode of reproduction in the regime of small variance (2018) (3)
Relationship between Kaposi's sarcoma, Kaposi's sarcoma-associated herpesvirus and AIDS dementia complex. (2000) (3)
Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers (2021) (2)
[Immunologic reconstruction after antiretroviral treatment]. (1999) (2)
[The discovery of three novel human viruses, human herpesviruses 6, 7, and 8]. (1997) (2)
NRTI-sparing regimens yield higher rates of drug resistance than NRTI-based regimens for HIV-1 treatment. (2014) (2)
Adaptation to a changing environment: what me Normal? (2022) (2)
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK (2016) (2)
Les tests de tropisme du VIH à l’heure de la mise à disposition du 1er anti-CCR5 (2008) (2)
[HHV-8/KSHV. II--Associated diseases]. (2000) (2)
Concentration in Lotka-Volterra parabolic equations: an asymptotic-preserving scheme (2022) (2)
Quantification des virus (1997) (2)
Predictive Genotypic Algorithm for Virologic Response to Lopinavir-Ritonavir in Protease Inhibitor-Experienced Patients (2008) (2)
Concentration Waves of Chemotactic Bacteria: The Discrete Velocity Case (2018) (2)
Influence of the mode of reproduction on dispersal evolution during species invasion (2020) (2)
Bimodality, prion aggregates infectivity and prediction of strain phenomenon (2008) (2)
Mathematical Modeling of Cell Collective Motion Triggered By Self-Generated Gradients (2021) (2)
INDEED study: final results of an induction treatment strategy with enfuvirtide in treatment failure patients (2008) (2)
Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen (2018) (2)
Blow-Up Phenomena for Gradient Flows of Discrete Homogeneous Functionals (2016) (2)
[Cognitive disorders in AIDS: clinical, virological and neuroradiological features]. (1998) (2)
Novel human herpesviruses (human herpesviruses 6, 7 and 8). (1996) (2)
[Conditions of "thymidine analog mutations" (TAMs) in naive patients treated with different combinations of d4T]. (2000) (2)
Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study. (2014) (2)
Reduction of a stochastic model of gene expression: Lagrangian dynamics gives access to basins of attraction as cell types and metastabilty (2021) (2)
Commentary: The Dynamics of Aerotaxis in a Simple Eukaryotic Model (2022) (2)
Chronic lymphocytic lymphoma and multiple myeloma in a patient infected with human herpesvirus 8 (HHV‐8) (2002) (2)
[Clinical importance of the quantification of HIV-1 RNA in cerebrospinal fluid for the diagnosis of HIV encephalitis]. (1998) (2)
[Resistance to antiretroviral agents: mechanism and study methods]. (1998) (2)
Propagation in a Kinetic Reaction-Transport Equation: Travelling Waves And Accelerating Fronts (2015) (2)
Ergodicity of the Fisher infinitesimal model with quadratic selection (2021) (1)
Prolonged replication of BA.1 and BA.2 Omicron lineages compared to Delta variant in nasopharyngeal samples from COVID-19 patients (2022) (1)
No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments. (2021) (1)
Efficacy of Lopinavir/ritonavir in Multiple PI-Experienced Patients According to Mutational Patterns: Data from the French ATU Program (2001) (1)
[Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor]. (1999) (1)
Kinetics of archived M184V mutation in treatment-experienced virally suppressed HIV-infected patients. (2021) (1)
Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial). (2020) (1)
Human retrovirus-5 and Sjögren's syndrome. (1999) (1)
Constant mitochondrial DNA levels in blood leukocytes of patients enrolled in a NRTI-free therapeutic trial (BIKS-2 study). (2007) (1)
Resistance to antiretroviral drugs. (1998) (1)
AIDS-associated Kaposi's sarcoma and HIV-protease inhibitors (1998) (1)
Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations (2022) (1)
Uniform contractivity of the Fisher infinitesimal model with strongly convex selection (2023) (1)
Characterization of drug resistance and the defective HIV reservoir in virally suppressed vertically infected children in Mali. (2020) (1)
A Single Amino-Acid Change in a Highly Conserved Motif of gp 41 Elicits HIV-1 Neutralization and Protects Against CD 4 Depletion (2013) (1)
Anti-retroviral therapies in advanced patients can restore CD4 T cell functions (1997) (1)
P.101 Unusual selection of rta181V HBV mutants cross-resistant to adefovir under lamivudine monotherapy: report of two cases (2006) (1)
Methods comparison for molecular diagnosis of human herpesvirus 8 infections. (2020) (1)
Darunavir resistance spectrum in darunavir-na#239;ve patients harboring virological failure to antiretroviral therapy (2010) (1)
Non-linear analysis of a model for yeast cell communication (2020) (1)
Modeling Edar expression reveals the hidden dynamics of tool signaling center patterning (2018) (1)
Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir (2017) (1)
Numerical simulation on a cell polarisation model: the polar case (2012) (1)
[Human herpesvirus 8 (HHV-8)]. (1999) (1)
Primaquine as a Candidate for HHV-8-Associated Primary Effusion Lymphoma and Kaposi’s Sarcoma Treatment (2022) (1)
Anti-SARS-CoV-2 swine glyco-humanized polyclonal antibody XAV-19 retains neutralizing activity against SARS-CoV-2 B.1.1.529 (Omicron) (2022) (1)
HIV-1 diagnosis with unquantifiable viraemia: don’t be naive, look for antiretroviral drugs (2017) (1)
CORRESPONDENCE Lack of evidence of an association between HHV-8 and multiple myeloma (1998) (1)
Adaptation of a quantitative trait to a changing environment: new analytical insights on the asexual and infinitesimal sexual models (2023) (0)
[The 8th human herpesvirus]. (1997) (0)
New Results - Tissue growth and cell movment (2006) (0)
Prevalence of human herpesvirus 8 antibodies in human immunodeficiency virus type 1-infected homosexual men in Slovakia. (1998) (0)
Human Herpesvirus 8 seroprevalence among blood donors in Mali (2022) (0)
Novel peptide derivatives, compositions and uses in the therapeutic treatment of infection by a herpesvirus (2004) (0)
116. Measuring the Effectiveness of Ergonomics (1999) (0)
Characterization of a Propionibacterium acnes Surface Protein as a Fibrinogen-Binding Protein (2017) (0)
Sarcome de Kaposi et HHV-8 (1996) (0)
Erratum to: Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients. (2021) (0)
[HHV-8 related diseases]. (1998) (0)
Phylodynamics of SARS-CoV-2 transmissions in France, Europe and the world during 2020 (2022) (0)
A RAINBOW INVERSE PROBLEM (2010) (0)
Effect of interleukin 2 treatment on hepatitis B and C infections (2001) (0)
Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study) (2018) (0)
G140S mutation rescues HIV-1 IN integration defect due to Q148H in vitro and in vivo (2009) (0)
High seroconversion rate and SARS-CoV-2 Delta neutralization in PLWHIV vaccinated with BNT162b2. (2021) (0)
Editorial CEMRACS 2018 (2020) (0)
Re-evaluation of resistance algorithms for lopinavir/ritonavir in the TITAN trial (2008) (0)
27372 Meclozine, a novel anti-inflammatory therapeutic in C acnes–induced inflammation in vitro and in vivo (2021) (0)
Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment (2014) (0)
Absence of HHV-8 infection in 37 patients with peripheral lymphedema. (2002) (0)
A well-balanced scheme for chemotactic travelling waves at the mesoscopic scale (2018) (0)
SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test (2022) (0)
Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virologic suppression (2017) (0)
Lymphocytes with Changes in Viral Load T + Dynamics of HIV-Specific CD8 (2014) (0)
P.413 How much does HIV co-infection impact on HCV viral load: influence of HCV genotypes and HIV infection markers (2006) (0)
[Therapeutic strategies for HIV infection: virology approach]. (2004) (0)
Nonlinear stability of chemotactic clustering with discontinuous advection (2020) (0)
New Results - Tissue growth, regeneration and cell movment (2008) (0)
[HIV tropism assays when first CCR5-antagonist becomes available]. (2008) (0)
[What is a virus?]. (1997) (0)
Perthame. Conservative cross diffusions and pattern formation through (2010) (0)
357 Cutibacterium acnes CAMP factor 1-related peptides as Toll-Like Receptor-2 modulators (2022) (0)
TRANSMISSION OF HUMAN HERPESVIRUS 8 THROUGH THE GRAFT. (2004) (0)
Replicationd Patients with Ongoing HIV-1 Dynamics and Coreceptor Usage in (2014) (0)
A P ] 1 9 D ec 2 00 7 The parabolic-parabolic Keller-Segel model in R 2 ∗ (2008) (0)
Stochastic and Deterministic Models for Evolutionary Biology (2016) (0)
Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment-experienced HIV-1 patients with virological success: DARDAR study (2010) (0)
Prevalence and risk factors of anal Human Papillomavirus infections among men having sex with men and transgender women in Phnom Penh, Cambodia. (2023) (0)
Substitutions intheCapsids ofPoliovirus Mutants Selected inHuman Neuroblastoma Cells Confer on theMahoneyType1 Strain aPhenotype Neurovirulent inMice (1994) (0)
A brake to reverse a gene drive invasion (2018) (0)
Establishment, characterization and Scid mice injection of B-cell lines harboring HHV-8 and EBV from a spleen of an HIV infected patient with multicentric Castleman's disease.: 65 (1997) (0)
Dynamics of the CD8 cytotoxic T cell differentiation and activation with HIV burden and anti-retroviral therapy (1997) (0)
Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients. (2021) (0)
An approach to change management (2003) (0)
SARS-CoV-2 variant-dependent inflammasome activation (2023) (0)
Characterization update of HIV-1 M subtypes diversity and proposal for subtypes A and D sub-subtypes reclassification (2018) (0)
Ultradeep sequencing in the therapeutic management of HIV-1 infection at treatment initiation. (2015) (0)
Replication Maraviroc-Treated Patients with Ongoing HIV-1 Dynamics and Coreceptor Usage in (2013) (0)
[Pathogenic and epidemiologic power of human herpesvirus 8 infections]. (2001) (0)
What aff ects the decisions of parents to allow their infant to participate in a therapeutic vaccine trial ? • What enrolment criteria and endpoints should be considered in a therapeutic vaccine trial that targets paediatric patients with HIV ? (2015) (0)
[Maternal-fetal viral infections: preventive treatment of maternal-fetal transmission during pregnancy, delivery and after birth]. (1999) (0)
Using INTERFERING RNA for the treatment of HIV infection (2009) (0)
Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens (2010) (0)
Large scale asymptotics of velocity-jump processes and non-local Hamilton-Jacobi equations (2016) (0)
TEACHING NOTE. Suicide or Work-related Accident? Let there be no Ceremony between Us! (2010) (0)
Cross-resistance to elvitegravir and dolutegravir in 502 patients failing to raltegravir (2014) (0)
More HIV-1 RNA detected and quantified with the Cobas 6800 system in patients on antiretroviral therapy. (2022) (0)
[The future of antiviral drugs]. (1997) (0)
PREDICTIVE FACTORS FOR DISEASE PROGRESSION AND DEATH IN AIDS RELATED KAPOSI'S SARCOMA. (1999) (0)
Abstract (2005) (0)
Direct cell-to-cell contact mediating upregulation of HIV-1 replication. (1996) (0)
Harnessing Redox Disruption to Treat Human Herpesvirus 8 (HHV-8) Related Malignancies (2022) (0)
New Results - Proliferation dynamics and its control (2011) (0)
Reconstitution immune sous traitements antirétroviraux de l'infection par le VIH (1999) (0)
Two models for yeast cell communication (2017) (0)
Antiretroviral resistance at virologic failure in the NEAT 001 / ANRS 143 trial : Raltegravir + 1 Darunavir / ritonavir or Tenofovir / Emtricitabine + Darunavir / ritonavir as first line 2 antiretroviral therapy 3 (2016) (0)
(Epi)mutation rates and the evolution of composite trait architectures (2022) (0)
Corrigendum: XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants (2023) (0)
High SARS-CoV-2 seroprevalence in HIV patients originating from sub-Saharan Africa in the Ile-de-France area (2022) (0)
LOW LEVEL OF BASELINE RESISTANCE IN RECENTLY HCV INFECTED MEN WHO HAVE SEX WITH MEN WITH HIGH-RISK BEHAVIORS. (2021) (0)
Inferring HIV-1 transmission networks and sources of epidemic spread in Africa with deep-sequence phylogenetic analysis (2019) (0)
Fatal disseminated kaposi sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients (2003) (0)
A New Topical Candidate in Acne Treatment: Characterization of the Meclozine Hydrochloride as an Anti-Inflammatory Compound from In Vitro to a Preliminary Clinical Study (2022) (0)
[Management of therapeutic failure in HIV-infected patients]. (2001) (0)
Uncommon Detection of Mixed HCV Genotype Infections in Recently Infected Men Who Have Sex with Men. (2019) (0)
High rate of Early HEV Seroconversion after Liver Transplantation among Cirrhotic Patients: Should We Test for it? (2023) (0)
Pattern selection in a biomechanical model for the growth of walled cells (2015) (0)
[New methods of quantification of the viral load in HIV infection]. (1995) (0)
Sequence Analysis of Reverse Transcriptase : Comparison with Conferring Resistance to Nucleoside Inhibitors Immunodeficiency Virus Type 1 Mutations Line Probe Assay for Detection of Human (1998) (0)
Reply to Ambrosioni et al. (2018) (0)
Phylodynamics of SARS-CoV-2 in France, Europe and the world in 2020 (2023) (0)
Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM programme (p 452-458) (2005) (0)
160 Severe primary HHV8 infection following transplantation with anti-HHV8-positive liver grafts (2004) (0)
Predictors and Outcomes of HIV-Infected Antiretroviral-Naive Patients With Discordant Responses to Combination Antiretroviral Treatment in Asian and Australian Populations : Results From APHOD (2011) (0)
Emergence of hepatitis C virus resistance associated variants in patients failing direct acting antivirals by ultra-deep sequencing (2018) (0)
Poppers by inducing HHV-8 virion production can act as a promoter for HHV-8 transmission in MSM (2021) (0)
A mathematical model of diffuse low-grade gliomas treated with PCV chemotherapy. (2011) (0)
Virus HHV-8/KSHV (2008) (0)
Presence of HIV-1 G-to-A mutations linked to APOBEC editing is more prevalent in non-B HIV-1 subtypes and is associated with lower HIV-1 reservoir. (2021) (0)
Infection par le virus HHV-8, maladie de Castleman et syndrome POEMS (1998) (0)
FRI0157 EPSTEIN BARR VIRUS BLOOD REPLICATION INCREASES DURING ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (2020) (0)
Prevalence of HIV-1 Natural Polymorphisms and Integrase-Resistance-Associated Mutations in African Children (2023) (0)
Optimizing the World Health Organization algorithm for HIV vertical transmission risk assessment by adding maternal self-reported antiretroviral therapy adherence (2022) (0)
Blow-Up Phenomena for Gradient Flows of Discrete Homogeneous Functionals (2017) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
Board – – – – — — – — — — — — — — IAS – USA Board of Directors — — — — – — — — — — (2018) (0)
Human herpes virus 8 : pathogenesis and epidemiology (2000) (0)

This paper list is powered by the following services:

Other Resources About Vincent Calvez

en.wikipedia.org

What Schools Are Affiliated With Vincent Calvez?

Vincent Calvez is affiliated with the following schools: